Abstract:Background: Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been administered as the first-line therapy for patients with EGFR mutations in LUAD, but it is almost inevitable that resistance to EGFR-TKIs therapy eventually arises. Polyphyllin I (PPI), derived from Paris polyphylla rhizomes, has been shown to have potent anti-cancer properties in a range of human cancer types including LUAD. However, the role of PPI in gefitinib resistance and the underlying mechanism remain elusive. Purpose: To evaluate the antitumor impacts of PPI on gefitinib resistance cells and investigate its molecular mechanism. Methods: CCK-8, wound healing, transwell assay, and xenograft model were performed to determine the anti-cancer effects of PPI as well as its ability to overcome gefitinib resistance. Immunoblotting, co-immunoprecipitation, phospho-RTK antibody array, qRT-PCR, and immunofluorescence were utilized to explore the mechanism by which PPI overrides gefitinib resistance. Results: PPI inhibited cell survival, growth, and migration/invasion in both gefitinib-sensitive (PC9) and -resistant (PC9/GR) LUAD cells (IC50 at 2.0 μM). Significantly, treatment with PPI at 1.0 μM resensitized the resistant cells to gefitinib. Moreover, cell-derived xenograft experiments revealed that the combination of PPI and gefitinib overcame gefitinib resistance. The phospho-RTK array and immunoblotting analyses showed PPI significant inhibition of the VEGFR2/p38 pathway. In addition, molecular docking suggested the interaction between PPI and HIF-1α. Mechanistically, PPI reduced the protein expression of HIF-1α in both normoxia and hypoxia conditions by triggering HIF-1α degradation. Moreover, HIF-1α protein but not mRNA level was elevated in gefitinib-resistant LUAD. We further demonstrated that PPI considerably facilitated the binding of HIF-1α to VHL. Conclusions: We present a novel discovery demonstrating that PPI effectively counteracts gefitinib resistance in LUAD by modulating the VEGF/VEGFR2/p38 pathway. Mechanistic investigations unveil that PPI facilitates the formation of the HIF-1α /VHL complex, leading to the degradation of HIF-1α and subsequent inhibition of angiogenesis. These findings uncover a previously unidentified mechanism governing HIF-1α expression in reaction to PPI, providing a promising method for therapeutic interventions targeting EGFR-TKI resistance in LUAD.

VDR Decrease Enhances the Efficacy of 1,25-Dihydroxyvitamin D3 Inhibiting Gefitinib Resistance by Regulating EGFR/FASN Loop in NSCLC Cells

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells

Combined Targeting Of The Estrogen Receptor And The Epidermal Growth Factor Receptor In Non-Small Cell Lung Cancer Shows Enhanced Antiproliferative Effects

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

Claudin1 Decrease Induced by 1,25-Dihydroxy-vitamin D3 Potentiates Gefitinib Resistance Therapy Through Inhibiting AKT Activation-Mediated Cancer Stem-Like Properties in NSCLC Cells.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

The Role of Up-Regulation of Integrin Β1 in Resistance to Gefitinib in Non-Small Cell Lung Cancer

Tumor Resistance to Anti-Vegf Therapy Through Up-Regulation of Vegf-C Expression

Role of Insulin-Like Growth Factor 1 in Drug Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer

Dha Increases The Anti-Tumor Effect Of Gefitinib On Non-Small Cell Lung Cancer With Egfr Mutations In Vitro

Zoledronic Acid Increases the Antitumor Effect of Gefitinib Treatment for Non-Small Cell Lung Cancer with Egfr Mutations

Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF

(Z)3,4,5,4′-Trans-tetramethoxystilbene, a New Analogue of Resveratrol, Inhibits Gefitinb-Resistant Non-Small Cell Lung Cancer Via Selectively Elevating Intracellular Calcium Level

HDGF Promotes Gefitinib Resistance by Activating the PI3K/AKT and MEK/ERK Signaling Pathways in Non-Small Cell Lung Cancer

Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma

3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer*

Phosphorylated Insulin-Like Growth Factor 1 Receptor is Implicated in Resistance to the Cytostatic Effect of Gefitinib in Colorectal Cancer Cells

Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis is a Key Mediator of Gefitinib-Acquired Resistance in EGFR-mutant Lung Cancer

Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non-Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway

H19 Overexpression Induces Resistance to 1,25(OH)2D3 by Targeting VDR Through Mir-675-5p in Colon Cancer Cells

Trans‐3,5,4´‐trimethoxystilbene Reduced Gefitinib Resistance in NSCLCs Via Suppressing MAPK/Akt/Bcl‐2 Pathway by Upregulation of Mir‐345 and Mir‐498